Results for T-Cell Receptor

Dr. Richman's research focuses on chimeric antigen receptor (CAR) T cells targeting solid tumors with the goal of translating these findings to this unmet clinical need.

Dr. Laetsch is a pediatric oncologist who provides clinical care and conducts research with the overarching goal of improving treatment options for children with difficult to treat cancers.

Dr. Tasian's research centers on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.

Dr. Schofield's research focuses on neurocognitive outcomes of oncology treatment. Her areas of interest are acute and long-term neurotoxicities and cognitive sequelae of cellular therapy, including hematopoietic stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy.

Dr. Tan uses experimental and computational approaches to study normal development and cancer. His laboratory is using the integrative approach to dissect the gene regulatory networks controlling embryonic hematopoiesis, T cell differentiation, and oncogenesis. He is also developing computational algorithms for constructing models of transcriptional regulatory and signaling networks by integrating multi-dimensional genomic, epigenomic, and transcriptomic datasets.